Literature DB >> 15237264

Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization.

Yuichi Teraki1, Tetsuo Shiohara.   

Abstract

BACKGROUND: Fixed drug eruption (FDE) is a distinct type of drug-induced eruption, in which intraepidermal CD8+ T cells in the lesional skin are the final effector cells in the epidermal injury of FDE. Desensitization is a unique approach for the management of drug eruption, which has been reported to be effective in treating FDE. However, the mechanisms underlying desensitization to FDE are quite unknown. OBJECTIVE AND METHODS: We reported a case of successful desensitization to allopurinol-induced FDE. To clarify the mechanisms underlying desensitization to FDE, we examined the phenotype of T cells in the epidermis of FDE lesions before and after desensitization using flow cytometry.
RESULTS: The overwhelming majority of intraepidermal T cells in the FDE lesion before desensitization consisted of CD8+ T cells, whereas a significant number of CD25+CD4+ T cells were present in the epidermis of FDE lesions after desensitization.
CONCLUSION: The presence of CD25+CD4+ T cells in the epidermis of FDE lesions may be involved in the induction of desensitization to FDE. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237264     DOI: 10.1159/000078583

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  12 in total

1.  Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption.

Authors:  Christine R F Rukasin; Elizabeth J Phillips; Allison E Norton
Journal:  Ann Allergy Asthma Immunol       Date:  2019-06-12       Impact factor: 6.347

2.  Clinical applications of drug desensitization in the Asia-Pacific region.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2011-04-26

3.  Desensitization to Oxcarbazepine: Long-Term Efficacy and Tolerability.

Authors:  Jiwon Lee; Eu Gene Park; Munhyang Lee; Jeehun Lee
Journal:  J Clin Neurol       Date:  2016-10-07       Impact factor: 3.077

4.  Drug desensitization in allergic children.

Authors:  Silvia Caimmi; Carlo Caffarelli; Francesca Saretta; Lucia Liotti; Giuseppe Crisafulli; Fabio Cardinale; Paolo Bottau; Francesca Mori; Fabrizio Franceschini; Roberto Bernardini; Gian Luigi Marseglia
Journal:  Acta Biomed       Date:  2019-01-28

5.  Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type.

Authors:  Aslı Gelincik; Semra Demir; Fatma Şen; Uğur Hamza Bozbey; Müge Olgaç; Derya Ünal; Bahauddin Çolakoğlu; Esin Çetin Aktaş; Günnur Deniz; Suna Büyüköztürk
Journal:  Asia Pac Allergy       Date:  2019-01-28

6.  Loss of tolerance 5 days after discontinuing sulphonamide introduced via desensitization in delayed reaction.

Authors:  Amanda Rocha Firmino Pereira; Marcelo Vivolo Aun; Nathália Coelho Portilho Kelmann; Antônio Abílio Motta; Jorge Kalil; Pedro Giavina-Bianchi
Journal:  Einstein (Sao Paulo)       Date:  2019-11-25

Review 7.  Drug allergy: causes and desensitization.

Authors:  Richard Warrington
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

8.  A case of allopurinol-induced fixed drug eruption confirmed with a lymphocyte transformation test.

Authors:  Min-Hye Kim; Eun-Jin Shim; Jae-Woo Jung; Seong-Wook Sohn; Hye-Ryun Kang
Journal:  Allergy Asthma Immunol Res       Date:  2012-03-29       Impact factor: 5.764

Review 9.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

10.  Reintroduction of oxcarbazepine after allergic reaction in two pediatric patients with epilepsy.

Authors:  Lingyan Yu; Zhiliang Wang; Zhenwei Yu; Jianhua Feng; Haibin Dai
Journal:  Ann Clin Transl Neurol       Date:  2021-06-28       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.